Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LONP1 | P36776 | 3/20 | 0.34 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GPR132 | Q9UNW8 | 3/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 2/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30759393 | 0.88 | LMNA (0.38) | LMNACYP3A4 | |
| SCHEMBL30759554 | 0.88 | KISS1R (0.41) | LONP1KISS1ROPRM1OPRD1REN | |
| SCHEMBL30759527 | 0.87 | OPRM1 (0.39) | KISS1ROPRM1OPRD1MMP12CTSL | |
| SCHEMBL30759358 | 0.86 | LONP1 (0.37) | LONP1MMP12CTSLCTSB | |
| SCHEMBL30759439 | 0.85 | KISS1R (0.41) | LONP1KISS1ROPRM1OPRD1REN | |
| SCHEMBL30759475 | 0.85 | PLG (0.35) | KISS1RLMNAGPR132OPRM1OPRD1 | |
| SCHEMBL31754278 | 0.82 | KISS1R (0.39) | KISS1ROPRM1OPRD1RENCTSL | |
| SCHEMBL31754333 | 0.81 | LONP1 (0.38) | LONP1MMP12CTSLCTSB | |
| SCHEMBL30759443 | 0.81 | KISS1R (0.45) | LONP1KISS1RREN | |
| SCHEMBL30759389 | 0.80 | KISS1R (0.42) | KISS1ROPRM1OPRD1RENMMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024020159-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | LONP1 1310/4885KISS1R 2731/4885LMNA 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.